13 new development(s) in neoantigen vaccines today.
50% off your first year of any Quiver subscription Backtested trading strategies built on Quiver's datasets Be the first to see our newest insights and key updates across all datasets Track the top-performing stock portfolios held by U.S. politicians in Congress Find stocks with …
2026 Half-Year Results and Business Update myvac® - Expanding potential across solid tumors through viral vector, AI driven neoantigen selection, and scalable cell-line manufacturing TG4050 - First Individualized Neoantigen Therapeutic Vaccine (INTV) from the myvac® platform adva…
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected, HPV-negative HNSCC. TG4050, a modified Vaccinia Ankara (MVA) viral vector–based individualized neoantigen therapeutic vaccine encoding up to 30 …
Scientists at the Lausanne University Hospital and the Ludwig Institute for Cancer Research have reported a striking proof of concept: a personalized neoantigen vaccine given to a patient with aggressive ovarian cancer not only provoked a durable immune response, but also served …
For decades, therapeutic cancer vaccines have promised to direct the immune system against cancer and establish durable tumor-specific memory. Yet early approaches targeting shared tumor-associated antigens rarely translated immune responses into meaningful clinical benefit, limi…
Peptide-HLA binding prediction is a critical step in neoantigen identification for personalized cancer immunotherapy and holds significant clinical value. However, the training data available for many HLA alleles are extremely limited, which severely constrains the performance of…
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group All 16 patients treated with an individualized cancer vaccine after surgery for locally advanced head and neck cancer remained disease-free aft…
Relevant work from earlier we're still surfacing — not today's news.